Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 4.46
NXTM's Cash-to-Debt is ranked higher than
64% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.69 vs. NXTM: 4.46 )
Ranked among companies with meaningful Cash-to-Debt only.
NXTM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.5  Med: 3.94 Max: No Debt
Current: 4.46
Equity-to-Asset 0.66
NXTM's Equity-to-Asset is ranked higher than
60% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. NXTM: 0.66 )
Ranked among companies with meaningful Equity-to-Asset only.
NXTM' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.58  Med: 0.62 Max: 0.89
Current: 0.66
-4.58
0.89
Debt-to-Equity 0.07
NXTM's Debt-to-Equity is ranked higher than
86% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.35 vs. NXTM: 0.07 )
Ranked among companies with meaningful Debt-to-Equity only.
NXTM' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.08  Med: 0.09 Max: 0.51
Current: 0.07
-0.08
0.51
Debt-to-EBITDA 0.50
NXTM's Debt-to-EBITDA is ranked higher than
82% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. NXTM: 0.50 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NXTM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -10.21  Med: 0.17 Max: 5.92
Current: 0.5
-10.21
5.92
Piotroski F-Score: 7
Altman Z-Score: 9.49
Beneish M-Score: -2.56
WACC vs ROIC
4.10%
-3.40%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -1.55
NXTM's Operating Margin % is ranked lower than
63% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.72 vs. NXTM: -1.55 )
Ranked among companies with meaningful Operating Margin % only.
NXTM' s Operating Margin % Range Over the Past 10 Years
Min: -100.2  Med: -7.25 Max: -1.17
Current: -1.55
-100.2
-1.17
Net Margin % -1.33
NXTM's Net Margin % is ranked lower than
63% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.03 vs. NXTM: -1.33 )
Ranked among companies with meaningful Net Margin % only.
NXTM' s Net Margin % Range Over the Past 10 Years
Min: -97.39  Med: -8.9 Max: -1.3
Current: -1.33
-97.39
-1.3
ROE % -2.46
NXTM's ROE % is ranked lower than
64% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.68 vs. NXTM: -2.46 )
Ranked among companies with meaningful ROE % only.
NXTM' s ROE % Range Over the Past 10 Years
Min: -54.8  Med: -13.28 Max: -2.43
Current: -2.46
-54.8
-2.43
ROA % -1.57
NXTM's ROA % is ranked lower than
62% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.36 vs. NXTM: -1.57 )
Ranked among companies with meaningful ROA % only.
NXTM' s ROA % Range Over the Past 10 Years
Min: -37.42  Med: -7.59 Max: -1.53
Current: -1.57
-37.42
-1.53
ROC (Joel Greenblatt) % -4.60
NXTM's ROC (Joel Greenblatt) % is ranked lower than
64% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.63 vs. NXTM: -4.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NXTM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -145.34  Med: -30.09 Max: -3.58
Current: -4.6
-145.34
-3.58
3-Year Revenue Growth Rate 9.10
NXTM's 3-Year Revenue Growth Rate is ranked higher than
70% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.90 vs. NXTM: 9.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NXTM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 9.5 Max: 332.9
Current: 9.1
0
332.9
3-Year EBITDA Growth Rate 58.60
NXTM's 3-Year EBITDA Growth Rate is ranked higher than
91% of the 146 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.70 vs. NXTM: 58.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NXTM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -61.9  Med: -21.05 Max: 58.6
Current: 58.6
-61.9
58.6
3-Year EPS without NRI Growth Rate -39.10
NXTM's 3-Year EPS without NRI Growth Rate is ranked lower than
93% of the 144 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.90 vs. NXTM: -39.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NXTM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -39.1  Med: -26.9 Max: 1.1
Current: -39.1
-39.1
1.1
GuruFocus has detected 3 Warning Signs with NxStage Medical Inc NXTM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NXTM's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

NXTM Guru Trades in Q3 2016

Alan Fournier 397,365 sh (New)
Jim Simons 250,983 sh (+58.37%)
Steven Cohen 200,000 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
» More
Q4 2016

NXTM Guru Trades in Q4 2016

Paul Tudor Jones 8,876 sh (New)
Alan Fournier 1,927,408 sh (+385.05%)
Jim Simons 84,783 sh (-66.22%)
» More
Q1 2017

NXTM Guru Trades in Q1 2017

Jim Simons 146,983 sh (+73.36%)
Alan Fournier 1,927,408 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2017

NXTM Guru Trades in Q2 2017

Steven Cohen 266,900 sh (New)
Alan Fournier 1,855,066 sh (-3.75%)
Jim Simons 14,783 sh (-89.94%)
» More
» Details

Insider Trades

Latest Guru Trades with NXTM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 334510    SIC: 3845
Compare:TSE:7732, FRA:PHH2, SZSE:002414, NAS:NVCR, NAS:MMSI, NYSE:HYH, NYSE:HAE, SZSE:300061, NAS:OSUR, XTER:GXI, NAS:ATRI, NAS:IRTC, NYSE:GKOS, TSE:3593, SZSE:300171, ROCO:1565, ASX:ANN, SZSE:300358, XKLS:7153, SZSE:300595 » details
Traded in other countries:N5X.Germany,
Headquarter Location:USA
NxStage Medical Inc is associated to the healthcare industry. It develops medical products for patients suffering from kidney failure.

NxStage Medical develops and manufactures products and services for patients with chronic or acute kidney failure. The firm operates in three segments: System One, In-Center, and Services. The System One segment contributes the majority of revenue. It sells and rents the System One portable hemodialysis systems and related consumable products for home and critical care hemodialysis treatments. The In-Center segment sells blood tubing sets and needles for hemodialysis, primarily to dialysis clinics. This business has a high degree of customer concentration. The Services business provides dialysis to customers at NxStage Kidney Care dialysis centers. NxStage generates the majority of its revenue in the United States.

Ratios

vs
industry
vs
history
Forward PE Ratio 250.00
NXTM's Forward PE Ratio is ranked lower than
100% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.51 vs. NXTM: 250.00 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 8.40
NXTM's PB Ratio is ranked lower than
84% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.25 vs. NXTM: 8.40 )
Ranked among companies with meaningful PB Ratio only.
NXTM' s PB Ratio Range Over the Past 10 Years
Min: 0.8  Med: 4.99 Max: 14.23
Current: 8.4
0.8
14.23
PS Ratio 4.75
NXTM's PS Ratio is ranked lower than
62% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.36 vs. NXTM: 4.75 )
Ranked among companies with meaningful PS Ratio only.
NXTM' s PS Ratio Range Over the Past 10 Years
Min: 0.66  Med: 3.59 Max: 16.32
Current: 4.75
0.66
16.32
Price-to-Operating-Cash-Flow 1524.46
NXTM's Price-to-Operating-Cash-Flow is ranked lower than
99% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.95 vs. NXTM: 1524.46 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NXTM' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 72.02  Med: 295.56 Max: 19340
Current: 1524.46
72.02
19340
EV-to-EBIT -301.29
NXTM's EV-to-EBIT is ranked lower than
99.99% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.17 vs. NXTM: -301.29 )
Ranked among companies with meaningful EV-to-EBIT only.
NXTM' s EV-to-EBIT Range Over the Past 10 Years
Min: -433.8  Med: -43.5 Max: -2.1
Current: -301.29
-433.8
-2.1
EV-to-EBITDA 63.24
NXTM's EV-to-EBITDA is ranked lower than
91% of the 134 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.83 vs. NXTM: 63.24 )
Ranked among companies with meaningful EV-to-EBITDA only.
NXTM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1804.3  Med: 52.85 Max: 478.5
Current: 63.24
-1804.3
478.5
EV-to-Revenue 4.70
NXTM's EV-to-Revenue is ranked lower than
59% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. NXTM: 4.70 )
Ranked among companies with meaningful EV-to-Revenue only.
NXTM' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.8  Med: 3.5 Max: 15.4
Current: 4.7
0.8
15.4
Current Ratio 3.34
NXTM's Current Ratio is ranked higher than
65% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.57 vs. NXTM: 3.34 )
Ranked among companies with meaningful Current Ratio only.
NXTM' s Current Ratio Range Over the Past 10 Years
Min: 1.71  Med: 3.09 Max: 10.96
Current: 3.34
1.71
10.96
Quick Ratio 2.24
NXTM's Quick Ratio is ranked higher than
61% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.88 vs. NXTM: 2.24 )
Ranked among companies with meaningful Quick Ratio only.
NXTM' s Quick Ratio Range Over the Past 10 Years
Min: 0.75  Med: 2.15 Max: 9.59
Current: 2.24
0.75
9.59
Days Inventory 78.40
NXTM's Days Inventory is ranked higher than
80% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 131.23 vs. NXTM: 78.40 )
Ranked among companies with meaningful Days Inventory only.
NXTM' s Days Inventory Range Over the Past 10 Years
Min: 72.56  Med: 85.16 Max: 111.72
Current: 78.4
72.56
111.72
Days Sales Outstanding 30.80
NXTM's Days Sales Outstanding is ranked higher than
90% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.37 vs. NXTM: 30.80 )
Ranked among companies with meaningful Days Sales Outstanding only.
NXTM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.56  Med: 28.95 Max: 48.64
Current: 30.8
26.56
48.64
Days Payable 25.04
NXTM's Days Payable is ranked lower than
88% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 51.31 vs. NXTM: 25.04 )
Ranked among companies with meaningful Days Payable only.
NXTM' s Days Payable Range Over the Past 10 Years
Min: 19.2  Med: 40.78 Max: 121.1
Current: 25.04
19.2
121.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.10
NXTM's 3-Year Average Share Buyback Ratio is ranked higher than
58% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.10 vs. NXTM: -2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NXTM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -143.2  Med: -8.2 Max: -2.1
Current: -2.1
-143.2
-2.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 41.58
NXTM's Price-to-Net-Current-Asset-Value is ranked lower than
93% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.73 vs. NXTM: 41.58 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NXTM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.77  Med: 46.26 Max: 112.06
Current: 41.58
2.77
112.06
Price-to-Tangible-Book 10.98
NXTM's Price-to-Tangible-Book is ranked lower than
81% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.82 vs. NXTM: 10.98 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NXTM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.38  Med: 7.44 Max: 107.91
Current: 10.98
2.38
107.91
Price-to-Median-PS-Value 1.32
NXTM's Price-to-Median-PS-Value is ranked lower than
63% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. NXTM: 1.32 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NXTM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.08 Max: 3.89
Current: 1.32
0.24
3.89
Earnings Yield (Greenblatt) % -0.33
NXTM's Earnings Yield (Greenblatt) % is ranked lower than
63% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.49 vs. NXTM: -0.33 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NXTM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -47.9  Med: -2.3 Max: -0.2
Current: -0.33
-47.9
-0.2
Forward Rate of Return (Yacktman) % 24.00
NXTM's Forward Rate of Return (Yacktman) % is ranked higher than
86% of the 97 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.48 vs. NXTM: 24.00 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NXTM' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -70.3  Med: -2.4 Max: 24.1
Current: 24
-70.3
24.1

More Statistics

Revenue (TTM) (Mil) $378.01
EPS (TTM) $ -0.07
Beta0.29
Short Percentage of Float2.69%
52-Week Range $20.45 - 30.80
Shares Outstanding (Mil)66.20

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 399 451
EPS ($) -0.04 0.11
EPS without NRI ($) -0.04 0.11
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAN
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}